Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma

Background: The standard treatment for metastatic renal cancer is based on vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTor) inhibitors. Compared to other advanced tumors, the treatment of renal cancer is highly affected by impaired renal function; therefore, patient...

Full description

Bibliographic Details
Main Authors:	Jindrich Kopecky, Alena Ticha, Hana Janeckova, Bohuslav Melichar
Format:	Article
Language:	English
Published:	Palacký University Olomouc, Faculty of Medicine and Dentistry 2018-11-01
Series:	Biomedical Papers
Subjects:	axitinib renal cancer chronic kidney failure hemodialysis protein-tyrosine kinases nephrectomy
Online Access:	https://biomed.papers.upol.cz/artkey/bio-201804-0014_hemodiafiltration_and_plasma_levels_of_axitinib_in_a_patient_with_metastatic_renal_clear_cell_carcinoma.php

Similar Items

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

HPLC method development and validation for the estimation of axitinibe in rabbit plasma
by: Achanta Suneetha, et al.
Published: (2017-10-01)

Axitinib in metastatic renal cell carcinoma: single center experience
by: Agnieszka Buraczewska, et al.
Published: (2017-01-01)

Axitinib in sequential therapy in metastatic renal cell carcinoma
by: Agata Kuchar, et al.
Published: (2015-05-01)

A Case of Metastatic Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome-Associated Renal Cell Carcinoma Treated with a Sequence of Axitinib and Nivolumab Following Cytoreductive Nephrectomy
by: Ichiro Yonese, et al.
Published: (2020-07-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2018-07-01)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
by: Chau V, et al.
Published: (2020-08-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
by: Masashi Kimura, et al.
Published: (2019-01-01)

Axitinib in the successive targeted therapy of patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2014-11-01)

Axitinib in the successive targeted therapy of patients with metastatic kidney cancer
by: B. Ya. Alekseev, et al.
Published: (2014-11-01)

Haemoglobin level increase as an efficacy biomarker during axitinib treatment for metastatic renal cell carcinoma: a retrospective study
by: Alison C. Johnson, et al.
Published: (2017-05-01)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
by: Narayan V, et al.
Published: (2016-03-01)

Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib
by: Linda Heintze, et al.
Published: (2020-11-01)

Combination of pembrolizumab and axitinib: a new gold standard in the first-line therapy for metastatic clear-cell renal-cell carcinoma?
by: R. A. Gafanov, et al.
Published: (2020-11-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report
by: Nobuaki Shimizu, et al.
Published: (2021-11-01)

The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
by: B. Ya. Alekseev, et al.
Published: (2021-06-01)

Second-line treatment with axitinib plus toripalimab in metastatic renal cell carcinoma: a retrospective multicenter study
by: Huang, J., et al.
Published: (2022)

Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment
by: Nanna Bæk Møller, et al.
Published: (2019-09-01)

The Changing Therapeutic Landscape of Metastatic Renal Cancer
by: Javier C. Angulo, et al.
Published: (2019-08-01)

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
by: Masatoshi Kudo, et al.
Published: (2021-04-01)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
by: Peiyao Lu, et al.
Published: (2020-05-01)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
by: Karakiewicz PI, et al.
Published: (2016-05-01)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study
by: Carmine D'Aniello, et al.
Published: (2016-09-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Patients with metastatic renal cell carcinoma who benefit from axitinib dose titration: analysis from a randomised, double-blind phase II study
by: Yoshihiko Tomita, et al.
Published: (2019-01-01)

Glioblastoma Cells Do Not Affect Axitinib-Dependent Senescence of HUVECs in a Transwell Coculture Model
by: Matilde Merolle, et al.
Published: (2020-02-01)

Neoadjuvant targeted therapy in patients with renal cell carcinoma
by: B. Ya. Alekseev, et al.
Published: (2015-06-01)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
by: Jane L. Roberts, et al.
Published: (2021-09-01)

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: results of matching-adjusted indirect comparison analyses
by: Irina Proskorovsky, et al.
Published: (2018-12-01)

Axitinib as a third or further line of treatment in renal cancer: a single institution experience
by: G. Tsironis, et al.
Published: (2020-06-01)

Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy
by: Akinori Nukui, et al.
Published: (2017-05-01)

Oxidative stress suppression contributes to antiseizure action of axitinib and rapamycin in pentylenetetrazol-induced kindling
by: O. B. Poshyvak, et al.
Published: (2021-04-01)

The efficacy and safety of the combination of axitinib and pembrolizumab‐activated autologous DC‐CIK cell immunotherapy for patients with advanced renal cell carcinoma: a phase 2 study
by: Meng‐Jia Song, et al.
Published: (2021-01-01)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
by: Valentina Giudice, et al.
Published: (2020-12-01)

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
by: Kai-Lin Yang, et al.
Published: (2021-01-01)